Refine by
Therapeutic Blocking Anaphylatoxin Receptor Antibodies Equipment & Supplies
47 equipment items found
Manufactured by:SYnAbs S.A. based inGosselies, BELGIUM
hC3aR expression on the immunocompetent rat cell line. In black: non transfected rat cell line with a mean fluorescence of 4400. In red: stably transfected rat cell line with a mean fluorescence of 563000. Labelling: anti hC3ar Biolegend + GAM ...
Manufactured by:Granite Bio AG based inBasel, SWITZERLAND
Novel Mode of Action: Depletion of pathogenic pro-inflammatory monocytes via ADCC/ADCP. First-in-class »Innate ...
Manufactured by:Granite Bio AG based inBasel, SWITZERLAND
Novel Therapeutic Target: Proprietary patient profiling identified novel disease biology node in inflammation, autoimmunity and ...
Manufactured by:PharmAbcine Inc. based inYuseong-gu, SOUTH KOREA
PharmAbcine’s fully human antibody library provides the diversity of antibody candidates for target antigens, ensuring highest success rates of developing therapeutic antibodies for various indications. Our unique and diverse antibody repertoires are constructed by recombination of V gene segments and DJ gene segments in human B-cell derived antibody heavy chains, generating more than 100 ...
Manufactured by:Creative Biolabs based inShirley, NEW YORK (USA)
Recombinant human monoclonal antibody expressed in CHO binding to human ANGPT2. Anti-ANGPT2 Therapeutic Antibody is a monoclonal antibody designed for the treatment of ...
by:Zymeworks Inc based inVancouver, BRITISH COLUMBIA (CANADA)
by creating tailored multifunctional therapeutics that enable enhanced efficacy and new biological approaches for treating diseases. Two is better than one. Create novel mechanisms of action through unique binding. Azymetric™ is the best-in-class platform for therapeutic antibodies that can simultaneously bind to multiple distinct locations on a target or to multiple targets, resulting in ...
Manufactured by:ProImmune Ltd. based inOxford, UNITED KINGDOM
Anti-Idiotype Ankyrons a game-changer for developing assays to track target-specific antibodies. Take the pain out of targeting the idiotype of your antibodies. Detecting and targeting specific antibody idiotypes is key for developing effective tracking assays for drug antibodies. Developing monoclonal and eventually recombinant anti-drug idiotype antibodies for such purposes has been possible ...
Manufactured by:Regeneron Pharmaceuticals Inc. based inTarrytown, NEW YORK (USA)
VelociMab is a group of technologies that allow us to move with unprecedented speed from identification of a therapeutic antibody into clinical studies. VelociMab enables the high-throughput screening of potential therapeutic antibodies and the rapid generation of cell lines for recombinant human antibodies. It allows researchers to go from mouse immunization to production cell line bioreactor ...
Manufactured by:Evox Therapeutics Limited based inOxford, UNITED KINGDOM
The Evox portfolio includes granted and pending applications in the world's major pharmaceutical markets, including USA, Europe, Japan, China as well as various other jurisdictions. In addition to the patent portfolio Evox also safeguards its intellectual property by the maintenance of several trademarks, copyrights, and trade secrets which together form broad and deep protection for the ...
by:Zymeworks Inc based inVancouver, BRITISH COLUMBIA (CANADA)
using precise antibody Fc modifications that tailor the antibody-mediated immune response. Get the optimal response. Tailor immune system response for a desired therapeutic effect using the Effector Function Enhancement and Control Technology’s (EFECT™) library of Fc region modifications. The EFECT™ library includes proprietary mutations to the CH2 domain of the antibody's Fc ...
Manufactured by:Kiadis Pharma NV based inAmsterdam, NETHERLANDS
Accessing a new repertoire of targets. Two classes of molecule with therapeutic potential that are not currently addressed by antibody drugs are G-protein-coupled receptors and ion channels, largely because they display small epitopes not accessible to traditional antibodies and their sequence is often conserved and thus less likely to be ...
Manufactured by:Krishgen Biosystems based inMumbai, INDIA
Adalimumab biosimilar is a recombinant human IgG1 monoclonal antibody specific for human tumor necrosis factor (TNF), was created using phage display technology resulting in an antibody with human derived heavy and light chain variable regions and human IgG1:k constant regions. Adalimumab biosimilar is produced by recombinant DNA technology in a mammalian cell (Chinese Hamster Ovary) expression ...
Manufactured by:Context Therapeutics Inc. based inPhiladelphia, PENNSYLVANIA (USA)
There is growing interest in applying antibody modalities including bispecifics, antibody-drug conjugates, and CART to solid tumors. However, identifying appropriate tumor-specific targets that avoid adverse effects in healthy tissue has been challenging. The tight junction protein Claudin 6 (CLDN6) is a validated therapeutic target for many solid tumor types, including ovarian, endometrial, ...
by:Zymeworks Inc based inVancouver, BRITISH COLUMBIA (CANADA)
with a modular suite of proprietary cytotoxins (cell-killing compounds), stable linkers, and conjugation technologies. A broader window of opportunity. Deliver potent cell-killing compounds specifically to diseased target cells with optimal safety and efficacy. ZymeLink™, a next-generation antibody drug conjugate (ADC) platform, is a suite of proprietary cytotoxins (cell-killing compounds), ...
Manufactured by:Eutilex Co.,Ltd. based inSeoul, SOUTH KOREA
Fully humanized therapeutic monoclonal antibody. This could convert type II macrophage to Type I. Anti-tumor efficacy of the antibody can be achieved by modulating tumor ...
Manufactured by:Ibio, Inc. based inBryan, TEXAS (USA)
Antibody discovery is challenging. Only 5 of every 5000 concepts make it into the clinic.1 Many antibody failures can be attributed to a lack of specificity for disease-causing cells versus healthy cells and a lack of efficacy – both potentially due to binding the wrong epitope. ...
Manufactured by:Lauren Sciences LLC based inNew York City, NEW YORK (USA)
V-Smart Platform, breakthrough innovation, winning trifecta for brain delivery, enables non-invasive, triple-targeted CNS delivery of non-BBB penetrant therapeutic agents (nucleic acids, antibodies, biologics, small molecules, ...
by:Starpharma Holdings Limited based inMelbourne, AUSTRALIA
Starpharma’s DEP® technology provides enhanced therapeutic benefits to Antibody Drug Conjugates (ADCs) including greater homogeneity, site specific attachment, and higher drug antibody ratio (DAR), than conventional ADC approaches. The use of ADCs is an innovative and cutting-edge area in cancer therapy that continues to grow, and Starpharma has a number of partner programs in the area. ...
Manufactured by:Jubilant Therapeutics Inc. based inBedminster, NEW JERSEY (USA)
Strong scientific and clinical rationale for PAD4 inhibitors in autoimmune ...
Manufactured by:BioFactura, Inc. based inFrederick, MARYLAND (USA)
With a mortality rate of over 30%, smallpox is one of the most dangerous biological threats. It is person-to-person airborne communicable, highly contagious and exhibits a long pre-symptomatic phase (12-14 days) allowing undetectable spread worldwide. While smallpox was declared eradicated in 1980 by the World Health Organization after an extensive vaccination campaign, the threat of bioterrorism ...